TCRX · Tscan Therapeutics Inc
United States · RS rating 3 · As of 2026-11-03
| Price | 0.19 USD |
|---|---|
| 1-day change | +5.6% |
| RS rating (overall / 1M / 3M / 12M) | 3 / 9 / 3 / 5 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 5 / 45 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +35.7% |
| Sales growth Q/Q | +2.2% |
| Distance from 52-week high | +86.8% |
| Market cap (USD) | $72.1M |